miR‐29b‐3p targetedly regulates VEGF to inhibit tumor progression and cisplatin resistance through Nrf2/HO‐1 signaling pathway in non‐small cell lung cancer
Environmental Toxicology · 2024-07 · 39 (7) · 3956-3966
DOI: 10.1002/tox.24253 ↗Kurz gefasst
Fachartikel in der Zeitschrift Environmental Toxicology, online erschienen am 08.04.2024. Verfasst von Zhen Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Cangzhou Central Hospital, Cangzhou, Hebei, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Cisplatin, NF-E2-Related Factor 2, MicroRNAs. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Backgrounds Non‐small cell lung carcinoma (NSCLC) is a common type of lung cancer. Prior investigations have elucidated the pivotal role of miR‐29b‐3p in restraining tumor growth and metastasis. Nonetheless, it remains to be determined whether miR‐29b‐3p can effectively suppress NSCLC progression and enhance the sensitivity of NSCLC cells to cisplatin. This investigation sought to determine the mechanism by which miR‐29b‐3p inhibited the advancement of NSCLC and mitigated resistance to cisplatin.
Methods
We initially assessed miR‐29b‐3p and VEGF levels in NSCLC tissues and cell lines. Next, miR‐29b‐3p expression was elevated in NSCLC cell lines H1975 and A549 by overexpression plasmid transfection. Following this, a sequence of molecular biology experiments was conducted to evaluate the impact of miR‐29b‐3p on the biological behaviors of NSCLC cells and their resistance to cisplatin. Additionally, we predicted VEGF was a target gene of miR‐29b‐3p by bioinformatics analysis. We next employed western blot to evaluate the protein expression of Nrf2 and HO‐1 in NSCLC cells. Finally, we elucidated the effects of VEGF and Nrf2/HO‐1pathway on NSCLC progression and cisplatin resistance by in vitro assays.
Results
In comparison to paracancerous tissues and human normal lung epithelial cells, the expression of miR‐29b‐3p was notably reduced and VEGF expression was clearly elevated in NSCLC tissues and cells. Moreover, miR‐29b‐3p upregulated obviously suppressed the biological activities of NSCLC cells and increased their sensitivity to cisplatin. Furthermore, in NSCLC cells, miR‐29b‐3p bound to VEGF and negatively regulate its transcription. Additionally, miR‐29b‐3p overexpression also inhibited the Nrf2/HO‐1 signaling pathway. Finally, the overexpression of VEGF and the activation of the Nrf2/HO‐1 pathway reversed miR‐29b‐3p‐mediated inhibitory effect on biological behaviors of NSCLC cells and increased the cisplatin resistance.
Conclusion
Our findings indicate that miR‐29b‐3p impedes NSCLC cells' biological behaviors and augments their sensitivity to cisplatin by targeting VEGF to modulate the Nfr2/HO‐1 signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Cangzhou Central Hospital, Cangzhou, Hebei, China.
- Department of Geriatrics, Cangzhou Central Hospital, Cangzhou, Hebei, China.
ORCID-Profile: Xiang Song
Zitieren
APA
Sun, Z., Ren, M., Niu, J., Tang, G., Li, Y., Kong, F., & Song, X. (2024). miR‐29b‐3p targetedly regulates VEGF to inhibit tumor progression and cisplatin resistance through Nrf2/HO‐1 signaling pathway in non‐small cell lung cancer. Environmental Toxicology, 39(7), 3956-3966. https://doi.org/10.1002/tox.24253
Vancouver
Sun Z, Ren M, Niu J, Tang G, Li Y, Kong F, et al. miR‐29b‐3p targetedly regulates VEGF to inhibit tumor progression and cisplatin resistance through Nrf2/HO‐1 signaling pathway in non‐small cell lung cancer. Environmental Toxicology. 2024;39(7):3956-3966. doi:10.1002/tox.24253
BibTeX
@article{Sun2024,
author = {Sun, Zhen and Ren, Mingming and Niu, Jieting and Tang, Guojie and Li, Yanguang and Kong, Fanyi and Song, Xiang},
title = {miR‐29b‐3p targetedly regulates VEGF to inhibit tumor progression and cisplatin resistance through Nrf2/HO‐1 signaling pathway in non‐small cell lung cancer},
journal = {Environmental Toxicology},
year = {2024},
volume = {39},
number = {7},
pages = {3956--3966},
doi = {10.1002/tox.24253}
}
EUVIMED